Next Article in Journal
Carbapenemase-Producing Raoultella Planticola: A Rare Cause of Pneumonia and Bacteremia
Previous Article in Journal
Prevention of Progression in Myopia: A Systematic Review
Open AccessFeature PaperReview

Anti-Diabetic Medications for the Pharmacologic Management of NAFLD

1
Department of Medicine, Roger Williams Medical Center, Providence, RI 02908, USA
2
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
3
Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19129, USA
4
Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA
5
Department of Medicine, Mary Imogene Bassett Hospital, Cooperstown, NY 13326, USA
6
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road # 210, Stanford, CA 94304, USA
*
Author to whom correspondence should be addressed.
Diseases 2018, 6(4), 93; https://doi.org/10.3390/diseases6040093
Received: 9 August 2018 / Revised: 5 September 2018 / Accepted: 28 September 2018 / Published: 3 October 2018
As a chronic disease encompassing a wide spectrum of liver-related histologic damage, nonalcoholic fatty liver disease (NAFLD) is becoming a global epidemic with significant impacts on all-cause morbidity and mortality. Insulin resistance and type 2 diabetes mellitus predispose individuals to NAFLD and related complications. Therefore, timely intervention with anti-diabetic medications may prevent and delay the development of NAFLD or have a therapeutic implication. The focus of this review is to evaluate the evidence supporting the efficacy of anti-diabetic medications in the treatment of NAFLD. While many of these anti-diabetic agents have shown to improve biochemical parameters, their effect on hepatic histology is limited. Among anti-diabetic medications, only thiazolidinediones and glucagon-like peptide-1 receptor agonists demonstrate significant improvement in hepatic histology. View Full-Text
Keywords: NAFLD; NASH; anti-diabetic medication; metformin; TZD NAFLD; NASH; anti-diabetic medication; metformin; TZD
MDPI and ACS Style

Cholankeril, R.; Patel, V.; Perumpail, B.J.; Yoo, E.R.; Iqbal, U.; Sallam, S.; Shah, N.D.; Kwong, W.; Kim, D.; Ahmed, A. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases 2018, 6, 93. https://doi.org/10.3390/diseases6040093

AMA Style

Cholankeril R, Patel V, Perumpail BJ, Yoo ER, Iqbal U, Sallam S, Shah ND, Kwong W, Kim D, Ahmed A. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases. 2018; 6(4):93. https://doi.org/10.3390/diseases6040093

Chicago/Turabian Style

Cholankeril, Rosann; Patel, Vikram; Perumpail, Brandon J.; Yoo, Eric R.; Iqbal, Umair; Sallam, Sandy; Shah, Neha D.; Kwong, Waiyee; Kim, Donghee; Ahmed, Aijaz. 2018. "Anti-Diabetic Medications for the Pharmacologic Management of NAFLD" Diseases 6, no. 4: 93. https://doi.org/10.3390/diseases6040093

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop